Overview

Docetaxel and Prednisone in Treating Patients With Hormone-Refractory Metastatic Prostate Cancer

Status:
Completed
Trial end date:
2010-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. It is not yet known which schedule of docetaxel and prednisone is more effective in treating prostate cancer. PURPOSE: This randomized phase III trial is studying two different schedules of docetaxel and prednisone to compare how well they work in treating patients with metastatic prostate cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Tampere University
University of Tampere
Treatments:
Docetaxel
Hormones
Prednisone